One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Physician–Patient Relationship
Arthur R. Derse, M.D., J.D.
doi : 10.1056/NEJMp2201630
Vol. 387 No. 8
Hospital Standards of Care for People with Substance Use Disorder
Honora Englander, M.D., and Corey S. Davis, J.D., M.S.P.H.
doi : 10.1056/NEJMp2204687
Improving the Use of FDA Advisory Committees
C. Joseph Ross Daval, J.D., Aaron S. Kesselheim, M.D., J.D., M.P.H., and Ameet Sarpatwari, Ph.D., J.D.
doi : 10.1056/NEJMp2206492
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
John P. Thornhill, M.D., Ph.D., Sapha Barkati, M.D., Sharon Walmsley, M.D., Juergen Rockstroh, M.D., Andrea Antinori, M.D., Luke B. Harrison, M.D., Ph.D., Romain Palich, M.D., Ph.D., Achyuta Nori, M.D., Iain Reeves, M.D., Maximillian S. Habibi, M.D., Ph.D., Vanessa Apea, M.D., M.P.H., Christoph Boesecke, M.D.,
doi : 10.1056/NEJMoa2207323
Before April 2022, monkeypox virus infection in humans was seldom reported outside African regions where it is endemic. Currently, cases are occurring worldwide. Transmission, risk factors, clinical presentation, and outcomes of infection are poorly defined.
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
Chirag D. Jhaveri, M.D., Adam R. Glassman, M.S., Frederick L. Ferris, III, M.D., Danni Liu, M.S.P.H., Maureen G. Maguire, Ph.D., John B. Allen, M.D., Carl W. Baker, M.D., David Browning, M.D., Ph.D., Matthew A. Cunningham, M.D., Scott M. Friedman, M.D., Lee M. Jampol, M.D., Dennis M. Marcus, M.D.,
doi : 10.1056/NEJMoa2204225
In eyes with diabetic macular edema, the relative efficacy of administering aflibercept monotherapy as compared with bevacizumab first with a switch to aflibercept if the eye condition does not improve sufficiently (a form of step therapy) is unclear.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Lawrence Steinman, M.D., Edward Fox, M.D., Ph.D., Hans-Peter Hartung, M.D., Enrique Alvarez, M.D., Ph.D., Peiqing Qian, M.D., Sibyl Wray, M.D., Derrick Robertson, M.D., DeRen Huang, M.D., Ph.D., Krzysztof Selmaj, M.D., Ph.D., Daniel Wynn, M.D., Gary Cutter, Ph.D., Koby Mok, Ph.D.,
doi : 10.1056/NEJMoa2201904
Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis
Josef S. Smolen, M.D., Eugen Feist, M.D., Saeed Fatenejad, M.D., Sergey A. Grishin, M.D., Ph.D., Elena V. Korneva, M.D., Ph.D., Evgeniy L. Nasonov, M.D., Mikhail Y. Samsonov, M.D., Ph.D., and Roy M. Fleischmann, M.D. for the CREDO2 Group*
doi : 10.1056/NEJMoa2201302
The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.
Lesions of the Ovary and Fallopian Tube
Rachel C. Sisodia, M.D., and Marcela G. del Carmen, M.D., M.P.H.
doi : 10.1056/NEJMra2108956
Tongue Telangiectasias in Systemic Sclerosis
Takeshi Zoshima, M.D., Ph.D., and Mitsuhiro Kawano, M.D., Ph.D.
doi : 10.1056/NEJMicm2117718
Relative Afferent Pupillary Defect
Sujatha Manjunathan, M.D., and Lokesh Saini, M.D., D.M.
doi : 10.1056/NEJMicm2120226
Case 26-2022: A 48-Year-Old Woman with Cystic Lung Disease
Krishna P. Reddy, M.D., Melissa C. Price, M.D., Jeffrey A. Barnes, M.D., Ph.D., Nancy A. Rigotti, M.D., and Rory K. Crotty, M.D.
doi : 10.1056/NEJMcpc2201247
Monkeypox — Past as Prologue
H. Clifford Lane, M.D., and Anthony S. Fauci, M.D.
doi : 10.1056/NEJMe2210535
Evidence for Step Therapy in Diabetic Macular Edema
David C. Musch, Ph.D., M.P.H., and Emily Y. Chew, M.D.
doi : 10.1056/NEJMe2208454
Audio Interview: Choosing an Antiviral to Treat Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2211254
When Silence Disrupts
Ryan C. Hunt, M.D., and Chava Kimchi-Sarfaty, Ph.D.
doi : 10.1056/NEJMcibr2207405
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis
doi : 10.1056/NEJMc2209529
